          |
 |
< Previous | 2023 Agenda and Abstracts | Next >
2023 OMIG Abstract
Purpose: To evaluate antibiotic resistance for Pseudomonas genus isolated from ocular samples over a 25-year timepoints.
Methods: All Pseudomonas isolates obtained from ocular samples were identified through database search of Vancouver Coastal Health Microbiology Department samples between 1997 and 2022. Type of sample, Gram smear, patient's demographics and antibiogram were collected. For analysis of trends, samples were clustered in 3 time periods (1997-2004, 2005-2013, 2014-2022).
Results: A total of 297 samples were identified. 35% came from corneal scraping, 29% unspecified, 18% conjunctiva, 6% lacrimal system, 5% contact lenses/contact lens cases, 4% orbit, 1% eyelid, 1% sclera, 1% vitreous. 38% came from right eye, 33% from left eye and 28% unknown. Over the three time periods, a progressive increase in resistance to Fluoroquinolones (3.8%, 4.7%, 9.4%) and in particular Moxifloxacin (0%, 18.4%, 25.8%) was observed in all samples, with resistance to Moxifloxacin reaching 32.5% in cornea and contact lens samples. Concomitantly, resistance to Ciprofloxacin remained between 1.8% and 3% in all samples and 0% in cornea and contact lens samples throughout the study period. Resistance to Tobramycin was reduced over the study period (2.6%, 1.8%, 0%).
Conclusions: This is the first study to identify increasing Pseudomonas resistance to Fluoroquinolones in North America, with particular regard to Moxifloxacin, over a 25 year timeframe. This follows trends observed in other geographic areas, as well as our clinical observations. Ciprofloxacin and Tobramycin remain viable anti-Pseudomonas drugs in our geographic area.
Disclosure:
N
< Previous | 2023 Agenda and Abstracts | Next > |
|
